A new manuscript from the IGNITE Pragmatic Trials Network has been published in JAMA Network Open, describing the primary results of the GUARDD-US study. GUARDD-US is a randomized controlled trial examining the impact of returning APOL1 genetic risk results to ...
Tuesday, September 27, 2022 | 11 am - 12 pm ET | Virtual Therapy-related neoplasms are recognized as a late effect of genotoxic exposure (cytotoxic chemotherapy or irradiation as a treatment for primary malignancy) or complication after solid organ transplant or treatment of autoimmune disorder. The importance of recognition of this type of neoplasms in […]
Wednesday, October 12, 2022 | 10:30 am - 6 pm ET | Virtual A planning committee of the National Academies of Sciences, Engineering, and Medicine will organize and conduct a public workshop to examine how genomic data are used in health care settings and to identify opportunities for advancement of precision health care delivery. The […]
Ensuring Fairness: At the Crossroads of Equity and Economic Considerations in Precision Medicine Tuesday, March 26 | 12 p.m. ET | Virtual Speaker: Kate Saylor, PhD Fellow, Ethical, Legal, and Social Implications (ELSI) of Genetics and Genomics, Perelman School of Medicine at the University of Pennsylvania Efforts to expand access to genomic health and precision medicine […]
Value of a Genomic Result in Rare Disease Patients – Sri Lankan Experience Thursday, June 27, 2024 | 9 a.m. ET | Virtual Speaker: Dr. Kawmadi Gunawardena Dr. Gunawardena will discuss the impact of genomic results in rare disease patients by illustrating interesting case scenarios of Sri Lankan patients. To learn more and register, visit the GGMC […]
GMKB